ALIGOS THERAPEUTICS ($ALGS) posted quarterly earnings results for Q4 2025 on Thursday, March 5th. The company reported earnings of -$1.91 per share, missing estimates of -$1.89 by $0.02. The company also reported revenue of $170,000, missing estimates of $816,000 by $-646,000.
You can see Quiver Quantitative's $ALGS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALIGOS THERAPEUTICS Hedge Fund Activity
We have seen 21 institutional investors add shares of ALIGOS THERAPEUTICS stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 268,664 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,503,948
- READYSTATE ASSET MANAGEMENT LP removed 203,113 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,893,013
- WOODLINE PARTNERS LP removed 179,030 shares (-38.2%) from their portfolio in Q4 2025, for an estimated $1,668,559
- TANG CAPITAL MANAGEMENT LLC removed 141,131 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,383,083
- SUMMITTX CAPITAL, L.P. added 139,424 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,299,431
- VERITION FUND MANAGEMENT LLC added 71,254 shares (+inf%) to their portfolio in Q4 2025, for an estimated $664,087
- TWO SIGMA INVESTMENTS, LP added 41,654 shares (+106.8%) to their portfolio in Q4 2025, for an estimated $388,215
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALIGOS THERAPEUTICS Government Contracts
We have seen $1,516,140 of award payments to $ALGS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ALIGOS THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ALGS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/12/2025
To track analyst ratings and price targets for ALIGOS THERAPEUTICS, check out Quiver Quantitative's $ALGS forecast page.
ALIGOS THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ALGS recently. We have seen 2 analysts offer price targets for $ALGS in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $20.0 on 01/07/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $50.0 on 09/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
